List of works - Tapan Kadia

A phase 1 dose‐escalation study of ARRY‐520, a kinesin spindle protein inhibitor, in patients with advanced myeloid leukemias ⬇️

scientific article published on December 2, 2011

A phase I and pharmacodynamic study of AT9283, a small-molecule inhibitor of aurora kinases in patients with relapsed/refractory leukemia or myelofibrosis

scientific article

A phase I/II study of the Janus kinase (JAK)1 and 2 inhibitor ruxolitinib in patients with relapsed or refractory acute myeloid leukemia

scientific article

A prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemia

scientific article

A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase

scientific article published on 10 August 2016

A randomized phase II study of low-dose decitabine versus low-dose azacitidine in lower risk MDS and MDS/MPN.

scientific article

Acquisition of cytogenetic abnormalities in patients with IPSS defined lower‐risk myelodysplastic syndrome is associated with poor prognosis and transformation to acute myelogenous leukemia ⬇️

scientific article published on July 23, 2013

Activating internal tandem duplication mutations of the fms-like tyrosine kinase-3 (FLT3-ITD) at complete response and relapse in patients with acute myeloid leukemia

scientific article published on 24 April 2012

Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies

scientific article published on 18 March 2016

Acute promyelocytic leukemia in a patient with chronic lymphocytic leukemia-A case report

scientific article published on 16 August 2017

Allogeneic hematopoietic stem cell transplantation versus hypomethylating agents in patients with myelodysplastic syndrome: a retrospective case-control study

scientific article

An exploratory clinical trial of bortezomib in patients with lower risk myelodysplastic syndromes

scientific article published on 31 March 2017

Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes

scientific article published on 5 February 2016

BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells

scientific article published on 28 September 2016

Biological and clinical features of trisomy 21 in adult patients with acute myeloid leukemia

scientific article

Bone marrow necrosis in acute leukemia: Clinical characteristic and outcome

scientific article

Case series of patients with acute myeloid leukemia receiving hypomethylation therapy and retrospectively found to have IDH1 or IDH2 mutations

scientific article

Central nervous system Richter's transformation and parvovirus B19 infection

scientific article

Characteristics and outcome of chronic myeloid leukemia patients with E255K/V BCR-ABL kinase domain mutations

scientific article published on 20 February 2018

Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML

scientific article

Clinical Experience of Venetoclax Combinations for Relapsed/Refractory Myeloid Malignancies

scientific article published in October 2017

Clinical Outcomes and Co-Occurring Mutations in Patients with RUNX1-Mutated Acute Myeloid Leukemia

scientific article published on 26 July 2017

Clinical Outcomes in Adult Patients with Aplastic Anemia- a single institution experience

scientific article published on 29 August 2017

Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal Dysfunction

scientific article published on 18 December 2015

Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosis

scientific article

Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents

scientific article published on 09 February 2016

Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients

scientific article published on 24 November 2015

Clofarabine plus low‐dose cytarabine followed by clofarabine plus low‐dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients ⬇️

scientific article published on January 26, 2012

Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia

scientific article

Clonal chromosomal abnormalities appearing in Philadelphia chromosome-negative metaphases during CML treatment

scientific article published on 23 August 2017

Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study

scientific article published on 29 September 2015

Cutaneous graft-versus-host disease after proton-based craniospinal irradiation for recurrent Philadelphia-positive acute lymphoblastic leukaemia ⬇️

scientific article published on July 11, 2012

Cytogenetic Evolution Associated With Disease Progression in Hematopoietic Neoplasms With t(8;22)(p11;q11)/BCR-FGFR1 Rearrangement

scientific article published in June 2016

Dapsone induced methemoglobinemia in a patient with glioblastoma

scientific article

Decitabine can be safely reduced after achievement of best objective response in patients with myelodysplastic syndrome

scientific article

Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes

scientific article published on 19 October 2015

Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype

scientific article published on 08 January 2016

Early detection of transformation to BPDCN in a patient with MDS

Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia

scientific article

FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia

scientific article

Factors associated with risk of central nervous system relapse in patients with non-core binding factor acute myeloid leukemia

scientific article published on 27 May 2017

Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia

scientific article published on 14 February 2015

Frontline treatment of acute myeloid leukemia in adults

scientific article published on 11 December 2016

Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma

scientific article

Hypocellular acute myeloid leukemia in adults: analysis of the clinical outcome of 123 patients ⬇️

scientific article published on November 4, 2011

Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agents

scientific article published on 11 January 2017

Impact of comorbidities by ACE-27 in the revised-IPSS for patients with myelodysplastic syndromes

scientific article

Impact of numerical variation in FMS-like tyrosine kinase receptor 3 internal tandem duplications on clinical outcome in normal karyotype acute myelogenous leukemia

scientific article

Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms

scientific article published on 3 January 2018

Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia

scientific article published on 11 July 2011

Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience

scientific article published on 6 January 2012

Incidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all-trans retinoic acid plus chemotherapy or with all-trans retinoic acid plus arsenic trioxide

scientific article published on 3 November 2014

Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study

scientific article published on 15 January 2018

Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia

scientific article published on 28 July 2010

Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents

scientific article published on 4 February 2014

Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia?

scholarly article by Musa Yilmaz et al published 16 January 2019 in Blood Cancer Journal

Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting

scientific article published on 3 October 2017

Liposomal Grb2 antisense oligodeoxynucleotide (BP1001) in patients with refractory or relapsed haematological malignancies: a single-centre, open-label, dose-escalation, phase 1/1b trial

scientific article published on 14 March 2018

Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab

scientific article published on 21 December 2016

Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls

scientific article

Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia

scientific article published on 22 October 2015

Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia

scientific article published on 11 May 2017

Mixed angioinvasive exserohilum and scedosporium infection in a patient with AML.

scientific article published on 24 June 2016

Modest activity of pomalidomide in patients with myelofibrosis and significant anemia

scientific article

More than 1 TP53 abnormality is a dominant characteristic of pure erythroid leukemia.

scientific article

Multiple recurrent extra-medullary relapses of high-grade diffuse large B-cell lymphoma presenting in acute leukemic phase

scientific article published on 5 March 2013

Mutated NPM1 in patients with acute myeloid leukemia in remission and relapse

scientific article

Myeloid neoplasms after breast cancer: "therapy-related" not an independent poor prognostic factor

scientific article

Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents

scientific article published on 26 May 2017

Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase

scientific article

Outcome of Patients With Therapy-Related Acute Myeloid Leukemia With or Without a History of Myelodysplasia

scientific article

Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium

scientific article

Outcomes of patients with myelodysplatic syndrome and chronic myelomonocytic leukemia post clofarabine failure

scientific article published on April 2014

Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemia

scientific article published on 17 January 2018

Peripheral blasts on day 21 of induction chemotherapy in a patient with core binding factor acute myeloid leukemia: more than meets the eye.

scientific article published on August 2010

Peripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapy

scientific article published on 30 July 2016

Persistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: prognostic significance and the potential role of allogeneic stem-cell transplantation

scientific article published on 09 May 2011

Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia

scientific article published on 22 September 2016

Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies

scientific article published on 2 May 2015

Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignancies

scientific article published on 8 August 2012

Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation

scientific article published on 23 April 2013

Phase 2 study of low-dose clofarabine plus cytarabine for patients with higher-risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents

scientific article published on 14 October 2016

Phase I and extension study of clofarabine plus cyclophosphamide in patients with relapsed/refractory acute lymphoblastic leukemia

scientific article

Phase I-II study of bendamustine in patients with acute leukemia and high risk myelodysplastic syndrome

scientific article

Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia

scientific article

Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome

scientific article

Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia

scientific article

Phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate‐1 risk myelodysplastic syndrome ⬇️

scientific article published on November 10, 2011

Phase II, open label, randomized comparative trial of ondansetron alone versus the combination of ondansetron and aprepitant for the prevention of nausea and vomiting in patients with hematologic malignancies receiving regimens containing high-dose c

Predicting survival of patients with hypocellular myelodysplastic syndrome: development of a disease-specific prognostic score system

scientific article

Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody

scientific article

Prognostic impact of RAS mutations in patients with myelodysplastic syndrome

scientific article

Prognostic implications of chromosome 17 abnormalities in the context of monosomal karyotype in patients with acute myeloid leukemia and complex cytogenetics

scientific article

Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors

scientific article

Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicin

scientific article

Prognostic significance of the Medical Research Council cytogenetic classification compared with the European LeukaemiaNet risk classification system in acute myeloid leukaemia

scientific article published on 25 February 2015

Residual DNA methylation at remission is prognostic in adult Philadelphia chromosome-negative acute lymphocytic leukemia

scientific article published on 23 December 2008

Retrospective analysis of prognostic factors associated with response and overall survival by baseline marrow blast percentage in patients with myelodysplastic syndromes treated with decitabine

scientific article

Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis

scientific article published on 18 June 2015

Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial

scientific article

Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study

scientific article published on 22 December 2014

Significance of recurrence of minimal residual disease detected by multi-parameter flow cytometry in patients with acute lymphoblastic leukemia in morphological remission

scientific article published on 4 January 2017

The combination of a histone deacetylase inhibitor with the BH3-mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy ⬇️

scientific article published on October 23, 2010

The combination of a histone deacetylase inhibitor with the Bcl-2 homology domain-3 mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy

scientific article published on 10 June 2010

The effect of decitabine dose modification and myelosuppression on response and survival in patients with myelodysplastic syndromes

scientific article

Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia

scientific article published on 24 April 2012

Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience

scholarly article by Kamal Chamoun et al published 3 January 2019 in Journal of Hematology & Oncology

Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase

scientific article published on 09 December 2013

Validation of a clinical assay of multi-locus DNA methylation for prognosis of newly diagnosed AML.

scientific article

Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome

scientific article published on 20 July 2017

List of works by Tapan Kadia

A phase 1 dose‐escalation study of ARRY‐520, a kinesin spindle protein inhibitor, in patients with advanced myeloid leukemias ⬇️

A phase I and pharmacodynamic study of AT9283, a small-molecule inhibitor of aurora kinases in patients with relapsed/refractory leukemia or myelofibrosis

A phase I/II study of the Janus kinase (JAK)1 and 2 inhibitor ruxolitinib in patients with relapsed or refractory acute myeloid leukemia

A prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemia

A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase

A randomized phase II study of low-dose decitabine versus low-dose azacitidine in lower risk MDS and MDS/MPN.

Acquisition of cytogenetic abnormalities in patients with IPSS defined lower‐risk myelodysplastic syndrome is associated with poor prognosis and transformation to acute myelogenous leukemia ⬇️

Activating internal tandem duplication mutations of the fms-like tyrosine kinase-3 (FLT3-ITD) at complete response and relapse in patients with acute myeloid leukemia

Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies

Acute promyelocytic leukemia in a patient with chronic lymphocytic leukemia-A case report

Allogeneic hematopoietic stem cell transplantation versus hypomethylating agents in patients with myelodysplastic syndrome: a retrospective case-control study

An exploratory clinical trial of bortezomib in patients with lower risk myelodysplastic syndromes

Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes

BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells

Biological and clinical features of trisomy 21 in adult patients with acute myeloid leukemia

Bone marrow necrosis in acute leukemia: Clinical characteristic and outcome

Case series of patients with acute myeloid leukemia receiving hypomethylation therapy and retrospectively found to have IDH1 or IDH2 mutations

Central nervous system Richter's transformation and parvovirus B19 infection

Characteristics and outcome of chronic myeloid leukemia patients with E255K/V BCR-ABL kinase domain mutations

Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML

Clinical Experience of Venetoclax Combinations for Relapsed/Refractory Myeloid Malignancies

Clinical Outcomes and Co-Occurring Mutations in Patients with RUNX1-Mutated Acute Myeloid Leukemia

Clinical Outcomes in Adult Patients with Aplastic Anemia- a single institution experience

Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal Dysfunction

Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosis

Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents

Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients

Clofarabine plus low‐dose cytarabine followed by clofarabine plus low‐dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients ⬇️

Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia

Clonal chromosomal abnormalities appearing in Philadelphia chromosome-negative metaphases during CML treatment

Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study

Cutaneous graft-versus-host disease after proton-based craniospinal irradiation for recurrent Philadelphia-positive acute lymphoblastic leukaemia ⬇️

Cytogenetic Evolution Associated With Disease Progression in Hematopoietic Neoplasms With t(8;22)(p11;q11)/BCR-FGFR1 Rearrangement

Dapsone induced methemoglobinemia in a patient with glioblastoma

Decitabine can be safely reduced after achievement of best objective response in patients with myelodysplastic syndrome

Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes

Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype

Early detection of transformation to BPDCN in a patient with MDS

Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia

FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia

Factors associated with risk of central nervous system relapse in patients with non-core binding factor acute myeloid leukemia

Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia

Frontline treatment of acute myeloid leukemia in adults

Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma

Hypocellular acute myeloid leukemia in adults: analysis of the clinical outcome of 123 patients ⬇️

Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agents

Impact of comorbidities by ACE-27 in the revised-IPSS for patients with myelodysplastic syndromes

Impact of numerical variation in FMS-like tyrosine kinase receptor 3 internal tandem duplications on clinical outcome in normal karyotype acute myelogenous leukemia

Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms

Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia

Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience

Incidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all-trans retinoic acid plus chemotherapy or with all-trans retinoic acid plus arsenic trioxide

Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study

Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia

Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents

Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia?

Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting

Liposomal Grb2 antisense oligodeoxynucleotide (BP1001) in patients with refractory or relapsed haematological malignancies: a single-centre, open-label, dose-escalation, phase 1/1b trial

Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab

Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls

Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia

Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia

Mixed angioinvasive exserohilum and scedosporium infection in a patient with AML.

Modest activity of pomalidomide in patients with myelofibrosis and significant anemia

More than 1 TP53 abnormality is a dominant characteristic of pure erythroid leukemia.

Multiple recurrent extra-medullary relapses of high-grade diffuse large B-cell lymphoma presenting in acute leukemic phase

Mutated NPM1 in patients with acute myeloid leukemia in remission and relapse

Myeloid neoplasms after breast cancer: "therapy-related" not an independent poor prognostic factor

Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents

Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase

Outcome of Patients With Therapy-Related Acute Myeloid Leukemia With or Without a History of Myelodysplasia

Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium

Outcomes of patients with myelodysplatic syndrome and chronic myelomonocytic leukemia post clofarabine failure

Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemia

Peripheral blasts on day 21 of induction chemotherapy in a patient with core binding factor acute myeloid leukemia: more than meets the eye.

Peripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapy

Persistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: prognostic significance and the potential role of allogeneic stem-cell transplantation

Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia

Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies